Cargando…

A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease

Classical non-insulin antihyperglycemic drugs currently approved for the treatment of type 2 diabetes mellitus (T2DM) comprise five groups: biguanides, sulfonylureas, meglitinides, glitazones and alpha-glucosidase inhibitors. Novel compounds are represented by the incretin mimetic drugs like glucago...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fisman, Enrique Z, Tenenbaum, Alexander
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723076/ https://www.ncbi.nlm.nih.gov/pubmed/19619327 http://dx.doi.org/10.1186/1475-2840-8-38

Ejemplares similares

Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes
por: Fisman, Enrique Z., et al.
Publicado: (2015)

Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?
por: Fisman, Enrique Z, et al.
Publicado: (2014)

Renal Outcomes Associated with the Use of Non-Insulin Antidiabetic Pharmacotherapy: A Review of Current Evidence and Recommendations
por: Elnaem, Mohamed Hassan, et al.
Publicado: (2020)

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter?
por: Tenenbaum, Alexander, et al.
Publicado: (2018)

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
por: Tenenbaum, Alexander, et al.
Publicado: (2005)

Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)
por: Tenenbaum, Alexander, et al.
Publicado: (2003)

Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
por: Tenenbaum, Alexander, et al.
Publicado: (2014)

Annual acknowledgement of manuscript reviewers
por: Tenenbaum, Alexander, et al.
Publicado: (2013)

Annual acknowledgement of manuscript reviewers
por: Tenenbaum, Alexander, et al.
Publicado: (2014)

Acknowledgement of manuscript reviewers 2014
por: Fisman, Enrique, et al.
Publicado: (2015)

The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes
por: Tschöpe, Diethelm, et al.
Publicado: (2013)

Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
por: Tenenbaum, Alexander, et al.
Publicado: (2004)

The ubiquitous interleukin-6: a time for reappraisal
por: Fisman, Enrique Z, et al.
Publicado: (2010)

"The metabolic syndrome... is dead": These reports are an exaggeration
por: Tenenbaum, Alexander, et al.
Publicado: (2011)

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study
por: Tenenbaum, Alexander, et al.
Publicado: (2010)

Mirroring the CANTOS revolution: is anti-inflammatory therapy for diabetes just around the corner?
por: Tenenbaum, Alexander, et al.
Publicado: (2017)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Fisman, Enrique Z., et al.
Publicado: (2021)

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
por: Tenenbaum, Alexander, et al.
Publicado: (2006)

Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes
por: Xu, James, et al.
Publicado: (2017)

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
por: Klempfner, Robert, et al.
Publicado: (2012)

Statins research unfinished saga: desirability versus feasibility
por: Fisman, Enrique Z, et al.
Publicado: (2005)

Losartan and diabetic nephropathy: commentaries on the RENAAL study
por: Fisman, Enrique Z, et al.
Publicado: (2002)

Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof
por: Fisman, Enrique Z, et al.
Publicado: (2003)

The Antidiabetic Functions of the Pancreas and Successful Isolation of the Antidiabetic Hormone Insulin
Publicado: (1924)

Revascularization outcomes in diabetic patients presenting with acute coronary syndrome with non-ST elevation
por: Ram, Eilon, et al.
Publicado: (2022)

Interventional Cardiology for Congenital Heart Disease
por: Kenny, Damien
Publicado: (2018)

Coronary calcium in patients with and without diabetes: first manifestation of acute or chronic coronary events is characterized by different calcification patterns
por: Shemesh, Joseph, et al.
Publicado: (2013)

Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19
por: Salmen, Teodor, et al.
Publicado: (2022)

Approaches to improve adherence to pharmacotherapy in patients with schizophrenia
por: Shuler, Kimberly M
Publicado: (2014)

Hypomagnesemia is associated with new-onset diabetes mellitus following heart transplantation
por: Peled, Yael, et al.
Publicado: (2019)

Current Pharmacotherapy and Multi-Target Approaches for Alzheimer’s Disease
por: Cheong, Siew Lee, et al.
Publicado: (2022)

Computational Cardiology: The Heart of the Matter
por: Trayanova, Natalia A.
Publicado: (2012)

Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation
por: Ram, Eilon, et al.
Publicado: (2019)

A Metabolomics Approach to Pharmacotherapy Personalization
por: Balashova, Elena E., et al.
Publicado: (2018)

A comprehensive review of chronic heart failure pharmacotherapy treatment approaches in African Americans
por: Tillman, Frank, et al.
Publicado: (2019)

Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial
por: Arbel, Yaron, et al.
Publicado: (2016)

Clinical Developmental Cardiology for Understanding Etiology of Congenital Heart Disease
por: Yamagishi, Hiroyuki
Publicado: (2022)

In-silico computational approaches to study microbiota impacts on diseases and pharmacotherapy
por: Shokri Garjan, Hassan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qgq90s4uel4iuohqa39nb1c5d6